COMPANY

Capricor, Inc.

HQ: San Diego, CA source · capricor.com ↗ · West Coast

Keywords: rare disease rare diseases Duchenne Muscular Dystrophy Heart Failure Muscular Dystrophies Atrophic Muscular Disorders Muscular Diseases Neuromuscular Diseases X-Linked Genetic Diseases Inborn Genetic Diseases Nervous System Diseases dilated cardiomyopathy Covid19 Cardiomyopathy Myocardial Infarction COVID-19 Renal Insufficiency Ischemic Cardiomyopathy Nonischemic Cardiomyopathy hypoplastic left heart syndrome acute myocardial infarction Deramiocel (CAP-1002) CAP-1002 Allogeneic Cardiosphere-Derived Cells (CAP-1002) CAP-1002 Allogeneic Cardiosphere-Derived Cells Allogeneic Cardiosphere-Derived Cells (CDCs)

Profile checked Oct 10, 2026

$86.3MRaised (2 yrs)11Trials (company is sponsor)8NIH grants

Timeline

Oct 18, 2024 Raise Follow-on offering: $86.3M (total, as published), announced Oct 18, 2024. Source: company release on GlobeNewswire. source ↗
Jun 22, 2022 Trial start Phase 3: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy source ↗
Nov 15, 2020 Trial start Phase 2: Intravenous Infusion of CAP-1002 in Patients With COVID-19 source ↗
Aug 5, 2020 Trial start Phase 2: Open-label Extension of the HOPE-2 Trial source ↗
Jun 21, 2018 Trial start Phase 2: Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) source ↗
Apr 4, 2018 Trial start Phase 2: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy source ↗
Jan 7, 2016 Trial start Phase 2: HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) source ↗
2015-12 Trial start Phase 1/Phase 2: Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment source ↗
2015-01 Trial start Phase 2: Safety Study of Cenderitide in Stable Chronic Heart Failure source ↗
2014-11 Trial start Phase 1: Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) source ↗
Nov 13, 2012 Trial start Phase 1/Phase 2: Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration source ↗

Funding

Raised: $86.3M. Last 2 years.

Oct 18, 2024 Follow-on offering: $86.3M (total, as published), announced Oct 18, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT04428476	Open-label Extension of the HOPE-2 Trial	Phase 2	Active, not recruiting	Aug 5, 2020	Feb 16, 2022 (actual)
NCT05126758	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 3	Active, not recruiting	Jun 22, 2022	Jun 18, 2025 (actual)
NCT03406780	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2	Completed	Apr 4, 2018	Mar 10, 2020 (actual)
NCT04623671	Intravenous Infusion of CAP-1002 in Patients With COVID-19	Phase 2	Completed	Nov 15, 2020	Feb 4, 2022 (actual)
NCT02485938	HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)	Phase 2	Completed	Jan 7, 2016	Sep 14, 2017 (actual)
NCT06304064	Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)	Phase 2	Completed	Jun 21, 2018	Mar 6, 2019 (actual)
NCT01458405	Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration	Phase 1/Phase 2	Terminated	Nov 13, 2012	Jul 3, 2017 (actual)
NCT04338347	CAP-1002 in Severe COVID-19 Disease	Not listed	No longer available	Not listed	Not listed
NCT02359227	Safety Study of Cenderitide in Stable Chronic Heart Failure	Phase 2	Completed	2015-01	Apr 2, 2015 (actual)
NCT02603614	Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment	Phase 1/Phase 2	Completed	2015-12	Mar 31, 2016 (actual)
NCT02293603	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)	Phase 1	Unknown status (ClinicalTrials.gov)	2014-11	2015-05 (actual)

NIH awards 8

Annual award amounts. Total $8.5M.

Sep 14, 2016 NIH award 1UT2HL131226-01 FY2016: $1,683,381 awarded for that fiscal year; activity UT2 (STTR); PI RODRIGUEZ-BORLADO, LUIS; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. The Allogeneic Heart Stem Cell Tria source ↗
Jul 8, 2015 NIH award 5R44HL095203-06 FY2015: $880,760 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Safety of Allogeneic Cardiosphere-D source ↗
Jun 24, 2014 NIH award 5R44HL095203-05 FY2014: $998,765 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Safety of Allogeneic Cardiosphere-D source ↗
Aug 21, 2013 NIH award 2R44HL095203-04 FY2013: $999,912 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Safety of Allogeneic Cardiosphere-D source ↗
Feb 29, 2012 NIH award 5R44HL095203-03 FY2012: $425,410 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Characterization and Potency of Opt source ↗
Feb 24, 2011 NIH award 4R44HL095203-02 FY2011: $397,217 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Characterization and Potency of Opt source ↗
May 13, 2010 NIH award 1RC3HL103356-01 FY2010: $2,993,268 awarded for that fiscal year; activity RC3 (OTHER_NIH); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Safety and Efficacy of Allog source ↗
Aug 25, 2009 NIH award 1R44HL095203-01A2 FY2009: $124,791 awarded for that fiscal year; activity R44 (SBIR); PI SMITH, RACHEL RUCKDESCHEL; recipient as written: CAPRICOR, INC., BEVERLY HILLS, CA. Characterization and Potency of O source ↗